Boothbay Fund Management LLC Boosts Holdings in Liquidia Technologies, Inc. $LQDA

Key Points

• Boothbay Fund Management LLC increased its holdings in Liquidia Technologies by 18.7% in the 1st quarter, owning approximately 662,873 shares valued at $9.8 million.
• The company reported a loss of $0.49 per share for the last quarter, missing estimates, but achieved a 141.5% increase in quarterly revenue compared to the previous year.
• Analysts have mixed views on Liquidia Technologies, with a consensus rating of "Buy" and an average price target of $32.11, with some analysts assigning a "strong-buy" rating.

Boothbay Fund Management LLC grew its stake in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) by 18.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 662,873 shares of the company's stock after purchasing an additional 104,215 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.78% of Liquidia Technologies worth $9,777,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of LQDA. Raymond James Financial Inc. acquired a new stake in Liquidia Technologies in the 4th quarter worth about $218,000. MetLife Investment Management LLC increased its holdings in shares of Liquidia Technologies by 14.8% in the fourth quarter. MetLife Investment Management LLC now owns 38,520 shares of the company's stock valued at $453,000 after purchasing an additional 4,969 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Liquidia Technologies by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,623 shares of the company's stock worth $290,000 after acquiring an additional 5,945 shares during the period. Tudor Investment Corp ET AL purchased a new position in Liquidia Technologies during the fourth quarter worth about $454,000. Finally, Northern Trust Corp lifted its holdings in Liquidia Technologies by 19.5% in the fourth quarter. Northern Trust Corp now owns 589,921 shares of the company's stock valued at $6,937,000 after acquiring an additional 96,381 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BTIG Research reissued a "buy" rating on shares of Liquidia Technologies in a research report on Tuesday, May 27th. Bank of America decreased their target price on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research report on Wednesday, June 11th. Scotiabank lifted their price target on shares of Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research report on Wednesday, May 28th. HC Wainwright boosted their price target on shares of Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, May 28th. Finally, Raymond James Financial upped their price objective on shares of Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Liquidia Technologies has an average rating of "Buy" and an average target price of $32.11.

Insider Buying and Selling

In other news, Director Paul B. Manning sold 328,268 shares of Liquidia Technologies stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $28.78, for a total value of $9,447,553.04. Following the completion of the transaction, the director owned 430,828 shares in the company, valued at approximately $12,399,229.84. This trade represents a 43.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $20.00, for a total transaction of $600,000.00. Following the transaction, the chief financial officer owned 376,412 shares of the company's stock, valued at $7,528,240. This trade represents a 7.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 835,573 shares of company stock worth $22,514,890 over the last ninety days. Company insiders own 30.10% of the company's stock.

Liquidia Technologies Stock Down 0.4%

Shares of LQDA traded down $0.12 during mid-day trading on Tuesday, hitting $27.86. 783,898 shares of the company's stock were exchanged, compared to its average volume of 1,816,304. The stock's 50-day moving average is $20.74 and its 200-day moving average is $16.87. The company has a debt-to-equity ratio of 9.84, a quick ratio of 2.41 and a current ratio of 2.49. Liquidia Technologies, Inc. has a fifty-two week low of $8.75 and a fifty-two week high of $29.94. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -16.39 and a beta of 0.22.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The business had revenue of $8.84 million during the quarter, compared to analyst estimates of $3.90 million. The business's quarterly revenue was up 141.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current fiscal year.

Liquidia Technologies Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).